Diversified Trust Co Invests $511,000 in 10x Genomics, Inc. (NASDAQ:TXG)

Diversified Trust Co acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 35,602 shares of the company’s stock, valued at approximately $511,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. grew its holdings in shares of 10x Genomics by 355.0% during the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock valued at $8,027,000 after buying an additional 277,355 shares during the last quarter. Geode Capital Management LLC lifted its position in 10x Genomics by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock valued at $41,009,000 after acquiring an additional 42,777 shares in the last quarter. M&T Bank Corp purchased a new stake in 10x Genomics during the 3rd quarter valued at $203,000. Barclays PLC increased its holdings in shares of 10x Genomics by 11.7% in the 3rd quarter. Barclays PLC now owns 602,536 shares of the company’s stock worth $13,605,000 after purchasing an additional 63,079 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of 10x Genomics in the third quarter worth $402,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Stock Down 1.6 %

NASDAQ TXG opened at $15.58 on Friday. 10x Genomics, Inc. has a 52 week low of $12.95 and a 52 week high of $51.22. The company has a market capitalization of $1.89 billion, a P/E ratio of -10.18 and a beta of 1.83. The stock’s 50-day moving average price is $15.08 and its 200-day moving average price is $18.10.

10x Genomics (NASDAQ:TXG) last released its earnings results on Tuesday, October 29th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company had revenue of $151.65 million for the quarter, compared to analysts’ expectations of $158.84 million. During the same quarter last year, the business earned ($0.51) EPS. The firm’s revenue was down 1.3% compared to the same quarter last year. Research analysts anticipate that 10x Genomics, Inc. will post -1.4 EPS for the current year.

Wall Street Analysts Forecast Growth

TXG has been the topic of several recent analyst reports. Barclays reduced their price objective on 10x Genomics from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, November 1st. The Goldman Sachs Group reduced their price target on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a research note on Wednesday, October 30th. Canaccord Genuity Group lowered their price objective on shares of 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, October 10th. Citigroup cut their target price on shares of 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lowered their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, 10x Genomics currently has an average rating of “Moderate Buy” and a consensus target price of $25.14.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.